BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, November 22, 2024
See today's BioWorld
Home
» SEC: Insider Trading Ring Led to $1.7M in Illegal Profits
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
SEC: Insider Trading Ring Led to $1.7M in Illegal Profits
Nov. 21, 2012
By
Catherine Shaffer
No Comments
According to the SEC, an insider trading ring based out of Celgene Corp., Sanofi SA and Stryker Corp. was counting on a lack of resources for enforcement at the agency to evade discovery. Those hopes were dashed Monday.
BioWorld